FUJIFILM Wako Chemicals Europe GmbH’s Post

“Moderate is better. CAR-Ts with moderate-affinity antigen-binding domains are more effective and have less off-target toxicity.” These findings from Rui Mao et al. published in Frontiers in Immunology intrigued me, a.o. because it seems so old-school to rely on binding affinity to characterise the potency of a cell therapy. Aren’t there more holistic approaches to assess the potency of a cell therapy? And preferably in such a form factor that it can be used during not only research and development but also as part of the routine manufacturing QC release? Looking forward to hearing your thoughts on this! imec.xpand #ATMP #potency #GeneTherapy #HealthTech #celltherapy #CARTcell #biotechnology #innovation #science

Check out our upcoming iPSC-Cardiomyocyte Webinar: Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) can be generated in nearly unlimited quantities. hiPSC-CMs have been validated for use in drug discovery projects and are replacing the use of animals in many instances, but limitations of this in vitro system have hindered widespread adoption of hiPSC-CMs for pre-clinical toxicity testing. One limitation is the immature phenotype of hiPSC-CMs. In this webinar, we present a human cell derived extracellular matrix (ECM) plating technology that solves this obstacle by promoting the maturation of hiPSC-CMs to a more in vivo state in only one week. Info and registration: https://hubs.li/Q02h0DH30

"We have developed a five-year strategy focusing on Ncardia’s strengths with the aim of becoming a world leader in stem cell applications. Our main purpose is to develop a focused portfolio of high-quality cells and ready-to-use assays for drug discovery, as well as manufacturing processes for cell supply and regenerative medicine applications. In the coming years, our company will establish and expand on these areas, utilizing proprietary technology and expertise developed over the past decade." Insightful interview with Dr. Jeroen De Groot, reflecting on his first 6 months as Divisional CEO of Ncardia! The conversation with him covered questions like: 🔶 2023 was an exciting year for Ncardia, what has changed and what's to come in the next five years? 🔶 What makes Ncardia unique? 🔶 How does Ncardia support drug and cell therapy developers? 🔶 Ncardia prides itself on being an all-around, long-term partner for drug discovery. How do you work with clients? 🔶 What are the most exciting current developments at Ncardia? Check out the full interview below (link in the comments) ⬇ #drugdiscovery #celltherapy #ipsc

Thank you to BioInformant for featuring Ncardia! Drug discovery involves high cost and uncertain outcomes. Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerge during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing. Now, some new medicines are being tested for safety on specialized cells developed from human pluripotent cell lines, and Ncardia is a clear market leader in this space. Link to the full article in the comments ⬇️ #drugdiscovery #stemcells #celltherapy BioInformant, Your Global Leader in Stem Cell Industry Data Cade Hildreth - BioInformant

We are so excited to announce our new partnership with growth factor manufacturer, Qkine! This collaboration will combine the expertise in complex protein manufacturing and engineering of Qkine with StemCultures, LLC. proprietary controlled-release technologies to develop new reagents for precision stem cell expansion and differentiation. "We are beginning to tackle the complexities of stem cell culture, where growth factors—proteins that provide essential signals to stem cells—degrade at varying rates, are inhibited by natural inhibitors accumulating in the culture, and are sequestered, leading to a fundamental lack of control over culture conditions. This lack of control affects the quality of data and scalability for disease models and the development of cell therapies." Dr. Catherine Elton, CEO and Founder of Qkine. #stemcells #organoids #growthfactors

Using a Vertical-Wheel Bioreactor to produce extracellular vesicles from human forebrain spheroids: in their latest work, Chang Liu, Yan Li at Florida State University and collaborators differentiated human induced pluripotent stem cells into forebrain spheroids using Vertical-Wheel Bioreactors. Extracellular vesicles were isolated from the spent culture media and characterised in terms of size, yield, purity, and biomarkers https://lnkd.in/eVxxbXbn Their protein and miRNA cargo profiles were further analysed through multi-omics approaches. This workflow opens new opportunities for utilising these EVs in drug delivery and cell-free therapies, particularly in preclinical applications. An article co-authored by Li Sun, Hannah Worden, Justice Ene, Olivia Zeng, Jamini B., Samuel Grant, Xiaoping Bao and Sunghoon Jung #extracellularvesicles #exosomes #bioreactor #stemcells #aggregates #Vesiculab

Incredible move by Recursion acquiring Exscientia for $688M! This deal signals a major shift from traditional Biotech to TechBio. The future is here, and #AI is at the forefront, revolutionizing drug discovery and development. At Somite Therapeutics.ai, we're thrilled to be part of this transformation, pushing the boundaries of stem cell therapeutics with cutting-edge AI. The best is yet to come! Other great companies are at the forefront, with e.g., Immunotherapy, cc Noam Solomon @ Immunai

Discover how using specific T cell subtypes as starting material can significantly improve CAR-T manufacturing. This article highlights the advantages of naive T cells and T memory stem cells, showing how these cells lead to enhanced efficacy and safety in CAR-T therapies. Curious to learn more about optimizing your CAR-T processes with these insights? Dive into the full article now! https://lnkd.in/g8-xN2nB #OCBio, #OrangeCountyBio, #CGT, #CellandGeneTherapy, #CellTherapy, #GeneTherapy, #Consulting, #Marketing

Did you know today is #PluripotencyDay? 🌱 #OCT4 is key when it comes to pluripotency, and at EditCo Bio, we’ve got you covered with reliable, edited iPS cells. Check our iPSC offerings here: https://hubs.la/Q02Sbp--0 #iPSCells #StemCells #GeneEditing #Biotech #Pluripotency #ScientificResearch #OCT4

Dive into the evolution of protocols for generating clinically relevant cell types from induced pluripotent stem cells (iPSCs) in this on-demand webcast. Get the insights, listen now. #iPSCells #StemCellResearch #GMP #Biotech #CellTherapy https://ow.ly/ziUA50TkuEH